Market ExpansionEyenovia's efforts to pursue an additional 200 active practices build on the current 230 offices for Mydcombi adoption, signaling potential expansion and increased market penetration.
Product DevelopmentCollaborations in dry eye disease development are seen as upside, with the user-filled Optejet potentially defining the most realistic shot for near-term progress.
Regulatory ApprovalEyenovia received its first Optejet delivery approval for Mydcombi, a fixed-dose combination ophthalmic mist spray, marking an important milestone for the company.